nelfinavir/Viracept / BID Cancer Research Results

NRF, nelfinavir/Viracept: Click to Expand ⟱
Features:
NRF is an antiretroviral medication used in the treatment of HIV/AIDS.
Nelfinavir belongs to the class of drugs known as protease inhibitors and like other PIs is almost always used in combination with other antiretroviral drugs.
BID, BH3 interacting-domain death agonist: Click to Expand ⟱
Source:
Type: pro-apoptotic protein
Bid is an abundant pro-apoptotic protein of the Bcl-2 family that is crucial for death receptor-mediated apoptosis in many cell systems.
The expression of BID can serve as a prognostic marker in several cancers. Higher levels of BID are often associated with increased apoptosis and better treatment responses, while lower levels may indicate resistance to therapy and poorer outcomes.

Generation of Truncated Bid (tBid):
• When apoptosis is signaled, specific proteases (such as caspase-8) cleave full-length Bid into its truncated form, tBid.
• tBid is the active form that translocates to mitochondria.

So "the truncation of Bid" means that the protein has been converted into an active form (tBid) that supports apoptosis.
Scientific Papers found: Click to Expand⟱
150- NRF,  CUR,  docx,    Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
- in-vitro, Pca, C4-2B
p‑Akt↓, p‑eIF2α↑, ER Stress↑, ATF4↑, CHOP↑, TRIB3↑, ChemoSen↑, Casp3↑, cl‑PARP↑, BID↑, XBP-1↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

p‑Akt↓, 1,   BID↑, 1,   Casp3↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Migration ⓘ

TRIB3↑, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers ⓘ

TRIB3↑, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: BID, BH3 interacting-domain death agonist
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:187  Target#:466  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page